Friday, 18 Oct 2019

You are here

Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis

A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious,  hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.

They studied 747 AS patients who initiated TNFI and/or DMARDs between 2001 and 2011 to identify hospitalized infection  coding data and hospital discharge diagnoses.

With nearly 2 years of follow-up there was 57 hospitalized infections (incidence rate of 2.9/100 person-years). 

The risk of hospitalized infection was not increased for those receiving TNFi (HZ = 1.00; 95% confidence interval 0.47–2.11) or DMARDs alone (HZ = 0.96 ;95% CI 0.45–2.04).

Risk was also linked to healthcare use, corticosteroids, and previous hospitalized infections.

These data add to the limited real world data on the risk of infection risk in AS patients  requiring more aggressive therapy. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Comorbidity Worsens Axial Spondyloarthritis

Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.

One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery

Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.

The Danish National Patient Registry was used in this cohort study of incident PsA patients and their future risk of joint surgery compared to a general population cohort (GPC) between 1995-2012).

FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis

The FUTURE 5 trial studied the effect of secukinumab (SEC) on radiographic progression through 52 weeks in patients with active psoriatic arthritis (PsA) and found that SEC was clinically and radiographically superior to placebo (PBO). Patients received s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. The majority (87%) of patients enrolled at baseline remained in the study for 52 weeks.

Ixekizumab vs. Adalimumab in Psoriatic Arthritis

The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.